Idiopathic Pulmonary Fibrosis

January 30, 2018January 30, 2018

FibroKine Inhaled Aerosol Delivery System for PF Awarded Early-stage Development Grant

The University of Pittsburgh’s Center for Medical Innovation (CMI) awarded a total of $115,000 to advance the development of five proposed solutions to medical conditions. One of the recipients is ... Read more

January 26, 2018January 26, 2018

Three Winners Will Share $1 Million for Innovation in IPF Catalyst Challenge

Idiopathic Pulmonary Fibrosis, News

Three companies will equally share $1 million for winning the IPF Catalyst Challenge, a competition that fosters innovative solutions for helping idiopathic pulmonary fibrosis (IPF) patients. The winners are Advanced Interactive Response Systems ... Read more

January 24, 2018January 24, 2018

Finalists for $1 million IPF Catalyst Challenge Includes patientMpower

Idiopathic Pulmonary Fibrosis, News

PatientMpower is one of the selected finalists of the IPF Catalyst Challenge to receive $1 million to fund research into idiopathic pulmonary fibrosis (IPF). The IPF Catalyst Challenge, being held ... Read more

January 23, 2018January 23, 2018

Interstitial Lung Disease Diagnoses Usually Inaccurate, Emotionally Trying, Patient Survey Shows

Idiopathic Pulmonary Fibrosis, News

A nationwide patient survey highlights the lengthy and often inaccurate diagnosis of interstitial lung disease (ILD), as well as the emotional stress it causes in patients. The research, “Barriers to ... Read more

January 22, 2018January 22, 2018

Pulmonary Fibrosis Foundation Expands National Care Center Network

Idiopathic Pulmonary Fibrosis, News

The Pulmonary Fibrosis Foundation (PFF) plans to expand its national PFF Care Center Network to further serve the community of patients, caregivers and loved ones affected by pulmonary fibrosis (PF). The ... Read more

January 17, 2018January 17, 2018

Health Canada Issues Safety Warning on Pulmonary Fibrosis Therapy Ofev

Idiopathic Pulmonary Fibrosis, News

Reports of liver injuries stemming from the pulmonary fibrosis therapy Ofev (nintedanib), including a fatality, have prompted Health Canada to issue a safety warning about it to medical professionals. The regulatory agency said ... Read more

January 15, 2018January 15, 2018

Owlstone Medical Among Finalists in IPF Catalyst Challenge

Idiopathic Pulmonary Fibrosis

Owlstone Medical is a finalist in the IPF Catalyst Challenge competition for $1 million in funding for advanced idiopathic pulmonary fibrosis research. The Catalyst Challenge aims to engage worldwide entrepreneurs ... Read more

January 11, 2018January 11, 2018

Bellerophon Enrolls First Patient in Study of INOpulse to Treat PH Linked to Interstitial Lung Disease

Idiopathic Pulmonary Fibrosis, News, Pulmonary Hypertension

A Phase 2b clinical study evaluating INOpulse as a treatment for pulmonary hypertension (PH) associated with interstitial lung disease (PH-ILD) enrolled the first patient, Bellerophon Therapeutics has announced. Patients with ... Read more

January 4, 2018January 4, 2018

FoxO3 Protein Found to Be Key Regulator of Fibrosis in Lungs, Study Finds

Idiopathic Pulmonary Fibrosis, News

The protein FoxO3, which regulates the levels of other proteins in cells, was found to play a key role in the development of pulmonary fibrosis, researchers reported. Results of the ... Read more

January 3, 2018January 3, 2018